PCSK9 and metabolic syndrome: After six months of add-on PCSK9-i therapy, only 42.9% of FH subjects attained LDL-C targets according to the European Society of Cardiology/European Atherosclerosis Society guidelines 2019 for the management of dyslipidemias.